Literature DB >> 1369522

Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs.

J K Kosovsky1, D T Matthiesen, S M Marretta, A K Patnaik.   

Abstract

Partial mandibulectomy was performed for the treatment of benign or malignant oral tumors in 142 dogs. Forty-two dogs with a benign tumor (ameloblastoma) had a 22.5 month (range, 6 to 74 months) median disease-free interval, with a 97% 1-year survival rate; there was local recurrence in one dog. Twenty-four dogs with squamous cell carcinoma had a disease-free interval of 26 months (range, 6 to 84 months), with a 91% 1-year survival rate; recurrence and metastasis developed in two dogs and metastatic disease in one dog. Based on survival curves, 37 dogs with a melanoma had a median survival time of 9.9 months (range, 1 to 36 months), with a 21% 1-year survival rate; 20 dogs died or were euthanatized for recurrent or metastatic disease. Twenty dogs with osteosarcoma had a median survival time of 13.6 months (range, 3 to 28 months), with a 35% 1-year survival rate; nine dogs died or were euthanatized for recurrent or metastatic disease. Nineteen dogs with fibrosarcoma had median survival time of 10.6 months (range, 3 to 32 months), with a 50% 1-year survival rate; 12 dogs died or were euthanatized for recurrent or metastatic disease. Results of this and previous studies demonstrated that partial mandibulectomy was effective in prolonging survival and decreasing recurrence for squamous cell carcinoma and ameloblastoma. Progressive disease and corresponding low survival times were common in dogs with melanoma, osteosarcoma, and fibrosarcoma. There were no differences in survival times or the progression of disease among five partial hemimandibulectomy procedures. The high rates of recurrence and metastasis in dogs with these tumors suggest a need for evaluation of ancillary chemotherapy and local radiation therapy to decrease the prevalence of progressive disease.

Entities:  

Mesh:

Year:  1991        PMID: 1369522     DOI: 10.1111/j.1532-950x.1991.tb00346.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  16 in total

Review 1.  Radiation therapy of canine nontonsillar squamous cell carcinoma.

Authors:  Candace K Grier; Monique N Mayer
Journal:  Can Vet J       Date:  2007-11       Impact factor: 1.008

2.  Three-Dimensional Printing-based Reconstruction of a Maxillary Bone Defect in a Dog Following Tumor Removal.

Authors:  Se Eun Kim; Kyung Mi Shim; Kwangsik Jang; Jin-Hyung Shim; Seong Soo Kang
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.

Authors:  Esther Chon; Brandi Flanagan; Lucas Campos de Sá Rodrigues; Caroline Piskun; Timothy J Stein
Journal:  Vet J       Date:  2014-07-31       Impact factor: 2.688

Review 4.  Treatment of Canine Oral Melanomas: A Critical Review of the Literature.

Authors:  Paolo Pazzi; Gerhard Steenkamp; Anouska J Rixon
Journal:  Vet Sci       Date:  2022-04-19

5.  Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).

Authors:  Mariateresa Camerino; Davide Giacobino; Luca Manassero; Selina Iussich; Federica Riccardo; Federica Cavallo; Lidia Tarone; Matteo Olimpo; Elena Lardone; Marina Martano; Sara Del Magno; Paolo Buracco; Emanuela Morello
Journal:  Vet Comp Oncol       Date:  2021-09-06       Impact factor: 2.385

Review 6.  Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review.

Authors:  Alissa Hendricks-Wenger; Lauren Arnold; Jessica Gannon; Alex Simon; Neha Singh; Hannah Sheppard; Margaret A Nagai-Singer; Khan Mohammad Imran; Kiho Lee; Sherrie Clark-Deener; Christopher Byron; Michael R Edwards; Martha M Larson; John H Rossmeisl; Sheryl L Coutermarsh-Ott; Kristin Eden; Nikolaos Dervisis; Shawna Klahn; Joanne Tuohy; Irving Coy Allen; Eli Vlaisavljevich
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2021-12-31       Impact factor: 3.267

7.  A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.

Authors:  Elisabetta Treggiari; Jessica Pauline Grant; Susan Margaret North
Journal:  J Vet Med Sci       Date:  2016-01-15       Impact factor: 1.267

8.  Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.

Authors:  L A Piras; F Riccardo; S Iussich; L Maniscalco; F Gattino; M Martano; E Morello; S Lorda Mayayo; V Rolih; F Garavaglia; R De Maria; E Lardone; F Collivignarelli; D Mignacca; D Giacobino; S Ferrone; F Cavallo; P Buracco
Journal:  Vet Comp Oncol       Date:  2016-05-04       Impact factor: 2.613

9.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

Authors:  Milan Milovancev; Stuart C Helfand; Kevin Marley; Cheri P Goodall; Christiane V Löhr; Shay Bracha
Journal:  BMC Vet Res       Date:  2016-06-04       Impact factor: 2.741

10.  Clinical features and treatment outcomes of 41 dogs with sublingual ectopic thyroid neoplasia.

Authors:  M R Broome; M E Peterson; J R Walker
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.